Relmada Therapeutics
RLMD
69 hedge funds and large institutions have $40.2M invested in Relmada Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 26 reducing their positions, and 15 closing their positions.
222% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $520K
1% less capital invested
Capital invested by funds: $40.7M → $40.2M (-$436K)
3.91% less ownership
Funds ownership: 44.93% → 41.02% (-3.9%)
13% less funds holding
Funds holding: 79 → 69 (-10)
58% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 26
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.61M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$938K |
| 3 |
SC
Shay Capital
New York
|
+$569K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$255K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$2.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.81M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$606K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$389K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$343K |
RLMD Hedge Fund Activity: Q3 2024 in Review
69 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2024, worth a combined $40.2M — down 1.1% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RLMD and 6 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, adding an estimated $1.61M. The largest seller was Vestal Point Capital, cutting an estimated $2.3M.
- 69 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2024, down from 79 in Q2 2024.
- Funds reported $40.2M of Relmada Therapeutics stock for Q3 2024, down 1.1% quarter-over-quarter.
- 6 funds opened new Relmada Therapeutics positions in Q3 2024 and 15 closed out, a net change of -9 holders.
- The largest Relmada Therapeutics buyer in Q3 2024 was Millennium Management, an estimated $1.61M added.
- The largest Relmada Therapeutics seller in Q3 2024 was Vestal Point Capital, an estimated $2.3M sold.
Based on aggregated 13F filings for Q3 2024.